Eli Lilly & Co. (LLY) News
Filter LLY News Items
LLY News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
LLY News Highlights
- LLY's 30 day story count now stands at 51.
- Over the past 27 days, the trend for LLY's stories per day has been choppy and unclear. It has oscillated between 1 and 11.
- The most mentioned tickers in articles about LLY are TEVA, RNA and CVS.
Latest LLY News From Around the Web
Below are the latest news stories about ELI LILLY & Co that investors may wish to consider to help them evaluate LLY as an investment opportunity.
Top Research Reports for Eli Lilly, Exxon Mobil & Lowe'sToday's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Exxon Mobil Corporation (XOM), and Lowe's Companies, Inc. (LOW). |
Lilly to Participate in the 2021 Cantor Virtual Global Healthcare ConferenceEli Lilly and Company (NYSE: LLY) will participate in the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021. Patrik Jonsson, senior vice president, president of Lilly Immunology and Lilly USA, and chief customer officer, will participate in a virtual fireside chat at 1:20 p.m., Eastern Time. |
Lilly to Present New Data from Oncology Portfolio at ESMO CongressNew data from various studies of Eli Lilly and Company's (NYSE: LLY) Verzenio® (abemaciclib), Retevmo® (selpercatinib) and CYRAMZA® (ramucirumab) will be presented at the European Society for Medical Oncology (ESMO) Congress 2021, to be held virtually September 16-21. Data will also be presented on Innovent's sintilimab, for which Lilly has an exclusive license for geographies outside of China. |
Why Eli Lilly's COVID Antibody Therapy Is Making a ComebackIn June, the U.S. government halted the distribution of Eli Lilly's (NYSE: LLY) COVID-19 antibody cocktail. The problem was that the therapy didn't seem to be effective against emerging coronavirus variants. In this Motley Fool Live video recorded on Sept. 1, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why Lilly's COVID antibody therapy is making a comeback. |
Lilly's (LLY) Jardiance Gets Breakthrough Therapy Tag for HFpEFThe FDA bestows a Breakthrough Therapy status on Lilly's (LLY) Jardiance for heart failure with preserved ejection fraction (HFpEF). |
Pharma Stock Roundup: SNY to Buy Kadmon, New Approvals for AZN & MRK's DrugsSanofi (SNY) offers $1.9 billion to buy Kadmon Holdings to strengthen its transplant business. AstraZeneca's (AZN) Ultomiris and Merck's (MRK) Keytruda get approvals for expanded use. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayGood morning, trader! |
Here's Why ProQR Stock Surged on ThursdayShares of ProQR Inc. (NASDAQ: PRQR), a clinical-stage biopharmaceutical company, soared 28% Thursday morning after announcing a new collaboration deal with Eli Lilly (NYSE: LLY). Eli Lilly agreed to pay ProQR up to $1.3 billion to develop RNA editing drugs aimed at up to five separate therapeutic targets. The deal is heavily backloaded with just $50 million upfront and approximately $1.25 billion in potential milestone payments. |
Biogen Stock Dives As CEO Admits 'Slower Than We Anticipated' Alzheimer's Drug LaunchBiogen stock tumbled Thursday after its CEO admitted the launch of Alzheimer's drug Aduhelm has been "slower than we anticipated." |
Lilly Prices First Sustainability Bond to Advance Global ESG StrategyEli Lilly and Company (NYSE: LLY) today announced the pricing of its first sustainability bond to advance its global environmental, social and governance (ESG) strategy to increase access to medicines, improve lives and communities, empower a diverse workforce, minimize environmental impact and operate ethically and responsibly. The company is issuing €600 million in aggregate principal amount of 0.50% notes with 12-year maturity, subject to customary closing conditions. |